Since the anti-HER3 mAbs in this study have shown positive reaction against CTOS, especially disrupted and reformed CTOS showing malignant cell growth phenotype [32], derived from human colon cancer (Figure 6D), these mAbs are promising for clinical development. This evidence concerns the gene ERBB3 and malignant colon neoplasm.